GlassScriptPhysician profile
Bethany Giudici Jessee
NPI 1336698414
$4,618.47
in general payments reported to CMS, 2019-2025
31 companies · $2,141 in 2025
The $2,141 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,190 · 2022: $76.95 · 2023: $105 · 2024: $1,105 · 2025: $2,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,351.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $577.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $518.00 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $508.46 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $441.15 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $358.69 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $318.38 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $282.62 | 2023-2025 | Veozah |
| Pfizer INC. | $202.24 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $158.84 | 2024-2025 | Voquezna |
| Lundbeck LLC | $154.78 | 2025 | Rexulti |
| Amarin Pharma, INC. | $148.81 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $129.83 | 2024-2025 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $102.57 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.47 | 2021-2025 | |
| Exact Sciences Corporation | $90.18 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.55 | 2022-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.32 | 2021-2025 | Xifaxan |
| Amgen INC. | $72.14 | 2021-2025 | Evenity, Prolia, Repatha |
| Vanda Pharmaceuticals INC. | $51.21 | 2025 | Fanapt |
| Sumitomo Pharma America, INC. | $35.37 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $29.59 | 2025 | Auvelity |
| Sanofi Pasteur INC. | $25.87 | 2025 | |
| Novartis Pharmaceuticals Corporation | $25.28 | 2023 | |
| Merck Sharp & Dohme LLC | $22.95 | 2021 | |
| Allergan, INC. | $17.33 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.70 | 2021 | |
| Eisai INC. | $15.50 | 2021 | |
| Currax Pharmaceuticals LLC | $15.22 | 2025 | Contrave, Onzetra Xsail |
| Genentech USA, INC. | $14.96 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.78 | 2021 | |
| Clarus Therapeutics INC. | $7.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Jessee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.